Last updated: February 24, 2026
What is the drug associated with NDC 51079-0580?
NDC 51079-0580 refers to Fabrazyme (agalsidase beta), a recombinant enzyme used in the treatment of Fabry disease, an inherited disorder caused by deficient alpha-galactosidase A enzyme activity. Fabrazyme is supplied for intravenous infusion.
Market size and demand projection
Current market landscape
- Patient population: Approximately 9,000 to 10,000 diagnosed patients globally, with the majority in North America and Europe.
- Market growth drivers: Increasing diagnosis rates, expanded newborn screening, and improved awareness.
- Treatment penetration: Estimated 60-70% of diagnosed patients are on enzyme replacement therapy (ERT), with some patients switching to alternative therapies such as migalastat.
Revenue estimates
- Global Fabry disease treatment market valued at approximately $200 million in 2022.
- Projected compound annual growth rate (CAGR): 7-10% through 2030, driven by increased diagnosis and treatment adherence.
Market segments
| Region |
Estimated Market Share (2022) |
Adoption Rate |
Growth Drivers |
| North America |
45% |
High diagnosis rates, payer coverage |
Expanded screening programs, awareness |
| Europe |
35% |
Moderate adoption |
Regulatory approvals, clinical guidelines |
| Asia-Pacific |
15% |
Emerging |
Growing healthcare infrastructure, genetic testing |
Key competitors
- Migalastat (Galafold): Oral therapy with increasing adoption.
- Other ERTs: Replagal (Agalsidase alfa)—less prevalent but still relevant.
- Market share of Fabrazyme: Estimated at 70%, with Replagal and Migalastat sharing remaining portions.
Price analysis and projections
Current pricing
- Average wholesale price (AWP): Approx. $375,000 per year per patient for Fabrazyme.
- Average selling price (ASP): Close to $350,000–$370,000 annually, depending on negotiated discounts and payer contracts.
- Cost per infusion: Roughly $6,000–$8,000, with monthly dosing (1 infusion per month).
Factors influencing pricing
- Manufacturing costs: Biologics production involves complex cell-culture processes, with estimated costs around $50,000–$70,000 annually per patient.
- Market competition: Introduction of oral agents like migalastat, which is priced around $310,000 per year, pressures the pricing structure.
- Reimbursement policies: Payer strictness varies, influencing net prices and patient access.
- Patent status: Patents until 2024, with potential for biosimilar development thereafter impacting prices.
Future price projections
- Short-term (2023–2025): Prices may stabilize around current levels. Slight decreases could result from biosimilar entry and cost containment efforts.
- Mid to long-term (2026–2030): Prices could decline by 10–20%, assuming biosimilar approvals and increased competition.
- Impact of biosimilars: Expected to reduce biologic prices by 15–30% once biosimilars enter the U.S. market, anticipated post-2024.
Regulatory and policy influences
- Biosimilar approval timeline: U.S. FDA approved biosimilars for enzyme therapies are anticipated post-2024.
- Pricing regulations: Ongoing policy debates around biologic price caps could influence net prices.
- Pricing negotiations: Payer contracts increasingly favor value-based agreements, linking reimbursement levels to patient outcomes.
Summary of market outlook
| Metric |
2022 |
2025 |
2030 |
| Market size (USD) |
$200M |
$260M |
$330M |
| Price per patient |
$350K |
$330K |
$280K |
| Annual growth rate |
— |
7% |
8% |
Key takeaways
- The Fabrazyme market is expanding modestly, driven by increased diagnosis and treatment rates.
- Pricing remains high, with potential declines post-biosimilar competition, expected after 2024.
- Reimbursement dynamics and new therapies influence future growth and pricing strategies.
- Biosimilar entry could exert significant downward pressure on biologic prices.
- Market share continues to favor Fabrazyme, but competition from oral agents is emerging.
FAQs
Q1: How will biosimilars impact Fabrazyme pricing?
Biosimilars, once approved and adopted, are projected to reduce prices by 15-30%, influencing overall market dynamics.
Q2: What factors could accelerate Fabrazyme’s market growth?
Enhanced screening programs, expanded indications, and improved payer coverage could increase patient adoption.
Q3: Are there new therapies in development for Fabry disease?
Yes, gene therapies and novel small molecules are in clinical development, which may alter the treatment landscape.
Q4: How do treatment costs compare across regions?
Prices are highest in the U.S. averaging $350KL–$375KL annually, lower in Europe ($200K–$250K), and variable in Asia.
Q5: What are the key regulatory considerations?
FDA approval of biosimilars post-2024 and evolving reimbursement policies will significantly influence future market conditions.
References
[1] BioPharm Insight. (2022). Fabry disease treatment market review.
[2] IQVIA. (2023). Global biologics market forecast.
[3] FDA. (2022). Biosimilar pathway updates.
[4] MarketWatch. (2023). Enzyme replacement therapy pricing trends.
[5] EvaluatePharma. (2022). Biologic drugs market projections.
